BRAINCHIP HOLDINGS LIMITED (BRN)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
BRN - BRAINCHIP HOLDINGS LIMITED
FNArena Sector :
Medical Equipment & Devices
Year End: June
GICS Industry Group : Software & Services
Debt/EBITDA: N/A
Index: ASX300 | ALL-ORDS | ALL-TECH
FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Software & Services
Debt/EBITDA: N/A
Brainchip Holdings is a holding company for its subsidiaries which provide neural computing technology and artificial neural networks through digital hardware and software. It operates in Australia and the US and has been a listed company since 2011.
LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
---|---|---|---|
$0.265
15 May |
-0.010 OPEN $0.28 |
-3.64% HIGH $0.29 |
4,179,270 LOW $0.27 |
OTHER COMPANIES IN THE SAME SECTOR | |||
4DX . AT1 . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VHT . VTI . |
FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
EPS Basic | xxx | xxx | xxx | xxx | xxx | -2.4 |
DPS All | xxx | xxx | xxx | xxx | xxx | 0.0 |
Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 0.3 M |
Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 1.4 |
Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | -26.4 M |
Net Profit Margin | xxx | xxx | xxx | xxx | xxx | -12,448.51 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -145.90 % |
Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -136.24 % |
Return on Assets | xxx | xxx | xxx | xxx | xxx | -119.86 % |
Return on Equity | xxx | xxx | xxx | xxx | xxx | -145.90 % |
Return on Total Capital | xxx | xxx | xxx | xxx | xxx | -128.51 % |
Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | -26.6 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 1 M |
Long Term Debt | xxx | xxx | xxx | xxx | xxx | 2 M |
Total Debt | xxx | xxx | xxx | xxx | xxx | 2 M |
Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | - |
Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 21 M |
Price To Book Value | xxx | xxx | xxx | xxx | xxx | 12.36 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capex | xxx | xxx | xxx | xxx | xxx | 0.2 M |
Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 57.16 % |
Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 1 M |
Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 41 M |
Research & Development | xxx | xxx | xxx | xxx | xxx | 9 M |
Investments - Total | xxx | xxx | xxx | xxx | xxx | - |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
BRN STOCK CHART
FNArena News on BRN
1 |
The Short Report – 07 Sep 2023Sep 07 2023 - Weekly Reports |
2 |
Next Week At A Glance – 22-26 May 2023May 19 2023 - Weekly Reports |
3 |
Artificial Intelligence On The ASXMay 02 2023 - Small Caps |
4 |
Rudi’s View: M&A Targets – Who’s Next?Feb 22 2023 - Rudi's View |
5 |
May In Review: Small Cap Shares UnderperformJun 06 2022 - Australia |
Latest Medical Equipment & Devices News
1 |
ResMed Silences The DoubtersApr 29 2024 - Australia |
2 |
Dr Boreham’s Crucible: 4D MedicalApr 23 2024 - Small Caps |
3 |
Uptrend Resumed For ResMedMar 19 2024 - Technicals |
4 |
Dr Boreham’s Crucible: CochlearFeb 28 2024 - Australia |
5 |
Rudi Interviewed: Ongoing Potential In Technology & GrowthFeb 19 2024 - Rudi's View |
6 |
Dr Boreham’s Crucible: ArtryaFeb 15 2024 - Small Caps |
7 |
ResMed Recovery Turns Into Hollywood ScriptJan 31 2024 - Australia |
8 |
ResMed Makes A ComebackJan 29 2024 - Australia |
9 |
ResMed: The Recovery Has BegunJan 23 2024 - Technicals |
10 |
Dr Boreham’s Crucible: Pro MedicusOct 23 2023 - Australia |